Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
← catalyst calendarNCT05382364 · readout in 133 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25actual
Sites
5
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-29 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic HER2+ Advanced Breast Cancer
- Breast Neoplasms
- Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
- Colorectal Cancer
Intervention
- Drug: Tucatinib — also filed as MK-7119
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with ≥1 adverse event (AE)
measured Up to approximately 2.5 years
Percentage of participants discontinuing from study therapy due to AE
measured Up to approximately 2.5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed